Active Ingredient(s): Tildrakizumab-asmn
FDA Approved: * March 20, 2018
Pharm Company: * MERCK SHARP DOHME
Category: Immune System

Tildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1] It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.[2][3][4] Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immun... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ilumya 100 mg/ml Subcutaneous Injection, Solution
NDC: 47335-177
Sun Pharma Global Fze